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Abstract: Intrahepatic cholangiocarcinoma (CCA) is characterized
by an abundant desmoplastic environment. Poor prognosis of CCA
has been associated with the presence of alpha-smooth muscle actin
(a-SMA)-positive myoﬁbroblasts (MFs) in the stroma and with the
sustained activation of the epidermal growth factor receptor (EGFR)
in tumor cells. Among EGFR ligands, heparin-binding epidermal
growth factor (HB-EGF) has emerged as a paracrine factor that con-
tributes to intercellular communications between MFs and tumor
cells in several cancers. This study was designed to test whether
hepatic MFs contributed to CCA progression through EGFR signaling.
The interplay between CCA cells and hepatic MFs was examined ﬁrst
in vivo, using subcutaneous xenografts into immunocompromised
mice. In these experiments, cotransplantation of CCA cells with
human liver myoﬁbroblasts (HLMFs) increased tumor incidence, size,
and metastatic dissemination of tumors. These effects were abolished
by geﬁtinib, an EGFR tyrosine kinase inhibitor. Immunohistochemical
analyses of human CCA tissues showed that stromal MFs expressed
HB-EGF, whereas EGFR was detected in cancer cells. In vitro, HLMFs
produced HB-EGF and their conditioned media induced EGFR activa-
tion and promoted disruption of adherens junctions, migratory and
invasive properties in CCA cells. These effects were abolished in theJournal of Hepatology 20
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HB-EGF, heparin-binding growth factor.presence of geﬁtinib or HB-EGF-neutralizing antibody. We also
showed that CCA cells produced transforming growth factor beta 1,
which, in turn, induced HB-EGF expression in HLMFs.
CONCLUSION: A reciprocal cross-talk between CCA cells and
myoﬁbroblasts through the HB-EGF/EGFR axis contributes to CCA
progression.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC)
are the two most common primary liver cancers worldwide [1]
and are malignancies that arise from epithelial cells that share
an early common developmental program. The risk of developing
CCA has been linked to liver ﬂukes and primary sclerosing
cholangitis (PSC), although most cases are thought to be sporadic
with chronic inﬂammation as a likely risk factor [2]. Cirrhosis is
the primary risk factor for HCC, and results from a chronic inﬂam-
matory ﬁbrotic milieu. This ‘microenvironment’ can be the conse-
quence of diverse diseases including viral hepatitis, chronic
alcoholism, metabolic syndrome, and inherited genetic muta-
tions. Rather than occurring in a background of cirrhosis, CCA is
often associated with desmoplasia, the deposition of ﬁbrotic or
connective tissue, which is frequently regarded as a response to
malignant cholangiocytes. However, carcinogenesis research has
illustrated the importance of the stroma or tumor microenviron-
ment in tumor progression resulting in re-evaluation of impact
of the ‘‘desmoplastic response’’ associated with CCA.
In other solid tumors (e.g., pancreatic, prostrate or breast car-
cinomas), the term ‘‘desmoplastic response’’ refers to the abnor-
mal activity of an epithelial neoplasia, wherein the tumor
stimulates stromal ﬁbroblasts to produce and deposit copious
amounts of collagens and extracellular matrix (ECM), which
surround the tumor. The desmoplastic stroma adjacent to these
cancers commonly includes activated alpha smooth muscle actin
(aSMA)-positive ﬁbroblasts, which produce ﬁbrillar collagens,
ﬁbronectins, proteoglycans, and tenascin C, in collaboration with
other liver cell types. Thus formation of stroma in CCA appears as
a secondary insult in response to malignant growth. Conversely,
in hepatocellular carcinogenesis, ﬁbrosis and cirrhosis are
thought to generate a microenvironment that promotes tumori-
genesis. Therapeutic implications for causal vs. consequential
role(s) of ﬁbrous tissue and collagenous stroma in liver tumors
are obvious. Surgical resection offers the only curative therapy
for either CCA or HCC, however few patients are cured of CCA14 vol. 61 j 432–434
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or HCC because of late detection of the tumor or high surgical
risk. Hence primary research goals for either liver malignancy
are to identify risk factors that enable earlier detection, and
deﬁne the molecular and cellular programs involved in their
respective pathogenesis to develop effective treatments.
The contribution of the stromal microenvironment to liver
carcinogenesis has been more fully appreciated in the last decade
(Fig. 1). In HCC molecular proﬁling studies from tumor and
adjacent cirrhotic liver indicate that the gene signature of the
adjacent non-tumor tissue contains critical molecular informa-
tion on recurrence and prognosis [3], indicating that molecular
prognostic determinants depend on both tumor and non-tumor
tissue. Analogous studies with CCA and adjacent liver have not
yet been performed, although CCA-genetic signatures have been
identiﬁed [4,5]. Recent studies in CCA development support the
notion that cancer-associated ﬁbroblasts (CAFs) promote tumor
progression [6]. While many different cell types inﬂuence the
tumor microenvironment, CAFs are fundamentally important byMyofibroblasts
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Fig. 1. Possible signaling interactions between myoﬁbroblasts (MFB) and canc
hepatocellular carcinoma (HCC). A hypothetical continuum is shown for the evolut
ligands are primary cytokines that activate quiescent HSCs, and perpetuate MFB and CA
and CAFs, which propagate CAF phenotype and promote tumorigenesis.
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the cellular architecture [7]. Yet the precise mechanisms by
which CAFs facilitate tumor progression and its molecular
evolution are not well understood. In particular, determining
the cellular origin(s) of CAFs and whether CAFs have different
functions when they participate in the desmoplastic response
in CCA compared to cirrhosis and subsequent HCCs will facilitate
novel therapeutic approaches. PSC may offer a unique vantage
point for CAF-pathogenesis studies. The sequential pathogenesis
in PSC, an autoimmune disease, begins with inﬂammation, bile
duct collapse and subsequent concentric ﬁbrosis. As CAFs are
present in advanced PSC, they may be a consequence of inﬂam-
mation and BEC cell death [8]. Recent cell fate tracing studies
indicate that HSCs are the primary ﬁbroblastic cell type in ﬁbro-
sis that give rise to myoﬁbroblasts regardless of mouse injury or
surgical models used [9]. Extension of cell fate mapping studies
to animal models of CCA or HCC with desmoplastic or ﬁbrotic
pathogenesis will be a next logical step.◦ TGFβ
◦ PDGFs
◦ EGF (e.g. HB-EGF)
◦ FGFs
◦ Integrins
◦ Hedgehog
◦ Mechanical forces
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ion of hepatic stellate cells (HSC) and myoﬁbroblasts to CAF. TGFb and PDGF
F phenotypes. Multiple paracrine signaling pathways exist between CCA and HCC
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A recent study furthers our mechanistic understanding of the
contribution of CAFs through the use of an admixture xenograph-
ic mouse model of CCA [10]. Clapéron and co-workers used a
combination of in vivo and in vitro approaches to show that
human hepatic myoﬁbroblasts promote the growth of human
CCAs. Human intrahepatic ﬁbroblasts were isolated from livers
from patients undergoing resection for metastases or benign
tumors, allowed to expand in vitro (termed human liver myoﬁ-
broblasts, HLMF) and then co-injected with human CCA cell lines
into immune-compromised mice. HLMFs stimulated CCA growth
in vivo and Geﬁtinib, a tyrosine kinase inhibitor (TKI) speciﬁc for
EGFR1, blunted xenograph growth illustrating that EGFR signal-
ing pathways contribute to CCA progression in this model. The
authors further demonstrated that heparin-binding EGF (HB-
EGF), one of the seven EGF ligands, was produced by HLMF and
promoted CCA growth.
The role of EGFR in carcinogenesis is well established [11,12],
yet challenges remain in developing selective therapies [13].
Genetic alterations in the EGFR ligand-receptor family have been
identiﬁed in CCA, including ampliﬁcations, deletions, and point
mutations [4,5] with ErbB1 being the primary focus of prior
investigations. The study by Clapéron and co-workers indicates
yet another mechanism by which EGFR pathways appears to con-
tribute to tumor progression, a mechanism whereby paracrine
signaling is perturbed. As with any ligand-receptor family, subtle
changes in cellular patterns of ligand or receptor expression man-
ifest in exaggerated cell growth or migration. In the Clapéron
study, HB-EGF expression was elevated in CCA specimens, in
the xenographic tumors, and in cultures of HLMF implicating
CAFs as a potential source of this EGF ligand. In vitro studies dem-
onstrate that HB-EGF binds to ErbB4/ErbB2 receptor heterodi-
mers in addition to ErbB1/ErbB2 dimers, albeit with a lower
afﬁnity [14] expanding possible EGFR pathways that could con-
tribute to CCA progression.
The admixture xenographic CCA model described by Clapéron
has a number of experimental advantages and therapeutic ent-
rées. It would be interesting to create a variety of cell mixtures
using different sources of human CAFs/HLMFs isolated from dif-
ferent etiologies or uninjured liver (e.g., quiescent HSCs). Will
CCA cell lines evoke a more dramatic ‘desmoplastic response’
from freshly isolated HSCs in vivo? Evidence from gene proﬁling
studies of isolated HSCs in human [15] and mice [16] suggest that
plastic-activation of HSCs does not fully recapitulate their in vivo
activation proﬁles. Thus use of ‘in vivo activated MFBs’ will likely
produce different results than plastic-activated MFBs. It would be
also be interesting to determine whether CAFs execute their
tumor-promoting effect when their numbers were less than
CCA tumor cells, which may tease apart autocrine or juxtacrine
signaling mechanisms from paracrine mechanisms. Therapeuti-
cally, CCA admixture xenographs could be used for testing com-
bination therapies with cytostatic TKIs and targeted monoclonal
antibodies to the various EFGR receptor isoforms.
As with any study using preclinical models, there are limita-
tions. In particular biliary architecture impacts the development
of CCA, and intrahepatic vs. extrahepatic CCA origin may be
important to delineate treatment [6,17]. A particular challenge
in CCA models is mimicking the in vivo topographical variation
observed in this malignancy. Themicroenvironmental mechanical434 Journal of Hepatology 201forces resulting from excess collagen and ECM deposition contin-
ually and reciprocally alter MFB and epithelial cell phenotypes.
How can the dynamically changing cellular architecture and
mechanical forces be modeled in vivo [7]? Nevertheless, the role
of CAFs in CCA and HCC progression will offer great insight into
the pathogenesis of these tumors.Conﬂict of interest
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